276 related articles for article (PubMed ID: 33766467)
1. Bladder cancer risk stratification using a urinary mRNA biomarker panel - A path towards cystoscopy triaging.
Shkolyar E; Zhao Q; Mach KE; Teslovich NC; Lee TJ; Cox S; Skinner EC; Lu Y; Liao JC
Urol Oncol; 2021 Aug; 39(8):497.e9-497.e15. PubMed ID: 33766467
[TBL] [Abstract][Full Text] [Related]
2. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Shepard B; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Ge S; Zhao S; Simon IM; Campbell SA; Rhees B; Bates MP; Higuchi RG; Witjes JA
Eur Urol; 2019 May; 75(5):853-860. PubMed ID: 30553612
[TBL] [Abstract][Full Text] [Related]
3. Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection.
Wallace E; Higuchi R; Satya M; McCann L; Sin MLY; Bridge JA; Wei H; Zhang J; Wong E; Hiar A; Mach KE; Scherr D; Egerdie RB; Ohta S; Sexton WJ; Meng MV; Weizer AZ; Woods M; Jansz GK; Zadra J; Lotan Y; Goldfarb B; Liao JC
J Urol; 2018 Mar; 199(3):655-662. PubMed ID: 29061538
[TBL] [Abstract][Full Text] [Related]
4. Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics.
Sin MLY; Mach KE; Sinha R; Wu F; Trivedi DR; Altobelli E; Jensen KC; Sahoo D; Lu Y; Liao JC
Clin Cancer Res; 2017 Jul; 23(14):3700-3710. PubMed ID: 28193625
[No Abstract] [Full Text] [Related]
5. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
6. Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts.
Brems-Eskildsen AS; Zieger K; Toldbod H; Holcomb C; Higuchi R; Mansilla F; Munksgaard PP; Borre M; Ørntoft TF; Dyrskjøt L
BMC Cancer; 2010 Nov; 10():646. PubMed ID: 21106093
[TBL] [Abstract][Full Text] [Related]
7. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
[TBL] [Abstract][Full Text] [Related]
8. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
9. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
Beukers W; van der Keur KA; Kandimalla R; Vergouwe Y; Steyerberg EW; Boormans JL; Jensen JB; Lorente JA; Real FX; Segersten U; Orntoft TF; Malats N; Malmström PU; Dyrskjot L; Zwarthoff EC
J Urol; 2017 Jun; 197(6):1410-1418. PubMed ID: 28049011
[TBL] [Abstract][Full Text] [Related]
10. A Urine Based Genomic Assay to Triage Patients with Hematuria for Cystoscopy.
van Kessel KEM; de Jong JJ; Ziel-van der Made ACJ; Roshani H; Haensel SM; Wolterbeek JH; Boevé ER; Oomens EHGM; van Casteren NJ; Krispin M; Boormans JL; Steyerberg EW; van Criekinge W; Zwarthoff EC
J Urol; 2020 Jul; 204(1):50-57. PubMed ID: 31985322
[TBL] [Abstract][Full Text] [Related]
11. Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer.
Liu C; Shi B; Hao C; Wang Q; Lv Q; Xing N; Shou J; Qu L; Gao Y; Qin C; Zhao J; Shou C
Oncotarget; 2016 Jul; 7(28):43432-43441. PubMed ID: 27223068
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer.
Koya M; Osborne S; Chemaslé C; Porten S; Schuckman A; Kennedy-Smith A
BMC Urol; 2020 Feb; 20(1):12. PubMed ID: 32046687
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic value of bladder cancer-related transcript markers in urine.
Schmidt J; Propping C; Siow WY; Lohse-Fischer A; Toma M; Baldauf-Twelker A; Hakenberg OW; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Feb; 142(2):401-14. PubMed ID: 26328914
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of semaphorin 3A in patients with urothelial cancer.
Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
[TBL] [Abstract][Full Text] [Related]
15. Urinary levels of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein as a diagnostic biomarker in patients with bladder cancer.
Nitta Y; Konishi H; Makino T; Tanaka T; Kawashima H; Iovanna JL; Nakatani T; Kiyama H
BMC Urol; 2012 Sep; 12():24. PubMed ID: 22943287
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
[TBL] [Abstract][Full Text] [Related]
18. Patients choose certainty over burden in bladder cancer surveillance.
van Osch FHM; Nekeman D; Aaronson NK; Billingham LJ; James ND; Cheng KK; Bryan RT; Zeegers MP
World J Urol; 2019 Dec; 37(12):2747-2753. PubMed ID: 30903352
[TBL] [Abstract][Full Text] [Related]
19. Urine CXCL1 as a biomarker for tumor detection and outcome prediction in bladder cancer.
Nakashima M; Matsui Y; Kobayashi T; Saito R; Hatahira S; Kawakami K; Nakamura E; Nishiyama H; Ogawa O
Cancer Biomark; 2015; 15(4):357-64. PubMed ID: 26406865
[TBL] [Abstract][Full Text] [Related]
20. Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria.
Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Lu X; Simon IM; Campbell SA; Bates MP; Higuchi RG; Witjes JA
Eur Urol Oncol; 2021 Feb; 4(1):93-101. PubMed ID: 33004290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
